Compare Advance Auto Parts, Inc. (AAP) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advance Auto Parts, Inc. vs Viatris Inc — how do they compare? Advance Auto Parts, Inc. trades at $53.42 (market cap $3.19B), while Viatris Inc trades at $16.14 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 5.9× Advance Auto Parts, Inc.'s market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| AAP | VTRS | |
|---|---|---|
Market Cap | $3.19B | $18.69B |
Sector | Consumer Cyclical | Health |
52-Week High | $64.17 | $17.86 |
52-Week Low | $38.75 | $9.49 |
Enterprise Value | $5.47B | $30.80B |
Dividend Yield | 1.89% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Advance Auto Parts (AAP) trades at $53.59, down 3.84% on the day, with a bearish technical signal. Recent earnings have consistently beaten estimates, but profitability remains thin with a net margin of 0.51%. The company is executing a turnaround focused on professional sales and supply chain restructuring. Cash flow trends show heavy financing activity supporting operations.
The outlook is mixed; analyst consensus is a Buy with a $61.30 price target, but high debt and weak operating cash flow pose risks. Upside depends on successful execution of the restructuring plan to improve margins and stabilize revenue. Near-term support is at $52, with resistance at $55.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Advance Auto Parts, Inc.
Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.
Read more on AAP →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
